Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC-L Vaccine and Ampligen in Recurrent Ovarian Cancer
NCT01312389Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Apr 2011
- Primary completion
- May 2012
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of autologous oxidized tumor cell lysate vaccine in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Abramson Cancer Center. Started Apr 2011; status: terminated.
02
Drugs
autologous oxidized tumor cell lysate vaccine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT01312389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01312389.